Oscar Tellez
07/15/2026
10:00 AM
The science around adipose-derived cells is evolving. This page summarizes where the research stands, in plain language and with honest limits. Banking preserves your own tissue now; it is not a treatment and does not guarantee access to any future therapy.
This page summarizes where research on adipose-derived and mesenchymal cells stands, in plain language and with honest limits. It covers active clinical trials, areas being studied, and what banking can and cannot do. Banking preserves your own tissue now. It is not a treatment, it does not enroll you in any trial, and it does not guarantee access to any future therapy.
Key takeaways:
Researchers around the world are studying adipose-derived and mesenchymal cells for a range of conditions. This work is investigational. It has not shown these cells to be safe or effective for those conditions, and none of these uses is FDA-approved. Banking preserves your own tissue; it does not enroll you in any study or treatment.
L2 Bio, the U.S.-based laboratory SaveMyFat works with, received FDA clearance in 2025 to begin a Phase 2b investigational clinical trial studying adipose-derived stem cells for Crohn’s disease. Read this carefully: an FDA-authorized trial is not an FDA-approved treatment. Clinical trials test safety and possible effectiveness under strict protocols, enrollment is controlled by investigators, participation is voluntary and requires informed consent, and many trials do not lead to approved therapies. Banking your tissue does not enroll you in this or any trial.
Researchers are studying whether mesenchymal and adipose-derived cells can influence immune activity. Conditions under study include multiple sclerosis and rheumatoid arthritis. This research is early and investigational, results vary, and none of these uses is FDA-approved. You can browse multiple sclerosis and mesenchymal cell trials on ClinicalTrials.gov.
Regenerative medicine is evolving, but progress is uncertain and slow. Some trials succeed; many do not. A recent example: darvadstrocel, an adipose-derived cell therapy for Crohn’s fistulas, did not meet its goals in a 2026 Phase 3 trial. A registered trial is not proof of safety or effectiveness, and it is not FDA approval. Banking preserves your own tissue now, without any promise about what the future holds.
Under certain legal and medical guidelines, eligible first-degree blood relatives may be considered for future use of your banked tissue. This is not guaranteed and would be decided by a physician within a lawful pathway. It does not mean any treatment is available now.
No one knows which options, if any, will be available in five or ten years. Banking preserves your own tissue now so it is documented and available if a lawful, FDA-regulated pathway ever applies. It is not a guarantee of access or benefit, and it is not a treatment.
It is easy to get excited about regenerative medicine headlines. Reading the research honestly matters more. Most studies of adipose-derived and mesenchymal cells are early stage, involve small numbers of patients, and report preliminary or mixed results. A study being registered on ClinicalTrials.gov means it is registered, not that the approach is proven, safe, effective, or FDA-approved.
Clinical trials test safety and possible effectiveness under strict scientific protocols. Enrollment is controlled by investigators with specific criteria, participation is voluntary and requires informed consent, and trials are research studies, not treatment programs. Many trials do not lead to approved therapies. As the FDA explains in its patient information on regenerative medicine therapies, most such products have not been shown to be safe or effective for the conditions they are marketed for. You can browse registered Crohn’s and mesenchymal cell trials on ClinicalTrials.gov. Banking your tissue does not enroll you in any of these.
See our directory of adipose stem cell clinical trials and, for the terms used here, the stem cell science glossary.
No. Banking preserves your own tissue; it does not provide or guarantee access to any treatment. Adipose-derived cell uses are investigational and not FDA-approved. Any future use would run through a lawful, FDA-regulated pathway decided by a physician.
Under certain legal and medical guidelines, eligible first-degree blood relatives may be considered for future use. Eligibility is not guaranteed and depends on the pathway, the relationship, and the regulations in place at that time.
Having tissue banked does not enroll you in a trial or entitle you to a treatment. Trials have their own eligibility criteria set by investigators, and approved therapies for these uses do not currently exist. Any future use would be decided by a physician within a lawful pathway.
Yes, which avoids the donor-matching questions associated with tissue from other people. It is not risk-free; collection carries normal procedure risks such as bruising or infection.
In FDA-compliant U.S. facilities with strict quality controls. SaveMyFat connects you with the bank; it does not process or store tissue itself. There is no overseas shipping.
Our network includes providers and laboratory partners with decades of combined experience in regenerative medicine, surgery, and tissue processing. Their involvement reflects our focus on U.S.-based, standards-driven handling of your tissue. Any future medical decision should be made with your own licensed provider.
Orthopedic Surgeon and Sports Medicine
Owner of Regenevada and Professor at UILC
Board-Certified General, Vascular & Cosmetic Surgeon
Whether you want to bank your own adipose tissue or offer banking in your practice, the next step is a conversation. We will walk you through the process, the costs, and the limits, so you can make an informed decision with your provider.
Bring compliant, U.S.-based adipose tissue banking to your organization.
Informed planning starts with one conversation.
Add a powerful service to your practice.
Our team can help you understand how adipose tissue banking works and what the research does and does not show. We do not provide medical advice; any medical decision is between you and a licensed physician.
Oscar Tellez is the founder and CEO of SaveMyFat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University and is a NASM Certified Personal Trainer. Oscar has spent more than a decade working across the regenerative medicine industry, including product distribution, laboratory and vendor relationships, and provider training. He founded SaveMyFat to connect patients and providers with compliant adipose tissue banking and to simplify the process. This article is educational, reflects current FDA guidance, and is not medical advice or a substitute for consultation with a licensed clinician.
Sources and further reading: U.S. FDA, Consumer Alert on Regenerative Medicine Products; FDA, Patient Information on Regenerative Medicine Therapies; 21 CFR Part 1271 (HCT/Ps); FDA Expanded Access; ClinicalTrials.gov.
Last reviewed: July 2026.
